180 related articles for article (PubMed ID: 31125357)
1. Adaptation of controlled attenuation parameter (CAP) measurement depth in morbidly obese patients addressed for bariatric surgery.
Somda S; Lebrun A; Tranchart H; Lamouri K; Prevot S; Njike-Nakseu M; Gaillard M; Lainas P; Balian A; Dagher I; Perlemuter G; Naveau S; Voican CS
PLoS One; 2019; 14(5):e0217093. PubMed ID: 31125357
[TBL] [Abstract][Full Text] [Related]
2. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
[TBL] [Abstract][Full Text] [Related]
4. Adaptation of liver stiffness measurement depth in bariatric surgery candidates with suspected nonalcoholic fatty liver disease.
Ciocan D; Lebrun A; Lamouri K; Pourcher G; Voican C; Njiké-Nakseu M; Ferretti S; Courie R; Tranchart H; Balian A; Prévot S; Perlemuter G; Dagher I; Naveau S
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):1014-20. PubMed ID: 27227687
[TBL] [Abstract][Full Text] [Related]
5. Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease.
Naveau S; Voican CS; Lebrun A; Gaillard M; Lamouri K; Njiké-Nakseu M; Courie R; Tranchart H; Balian A; Prévot S; Dagher I; Perlemuter G
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1022-1030. PubMed ID: 28570343
[TBL] [Abstract][Full Text] [Related]
6. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
Wan T; Köhn N; Kröll D; Berzigotti A
Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
[TBL] [Abstract][Full Text] [Related]
7. The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography.
de Barros F; Setúbal S; Martinho JM; Leite NC; Guaraná T; Monteiro ABS; Villela-Nogueira CA
Obes Surg; 2016 Sep; 26(9):2089-2097. PubMed ID: 26803754
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
9. Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study.
Parente DB; Perazzo H; Paiva FF; Campos CFF; Saboya CJ; Pereira SE; Silva FDE; Rodrigues RS; Perez RM
Sci Rep; 2020 Sep; 10(1):15007. PubMed ID: 32929103
[TBL] [Abstract][Full Text] [Related]
10. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity.
Ooi GJ; Earnest A; Kemp WW; Burton PR; Laurie C; Majeed A; Johnson N; McLean C; Roberts SK; Brown WA
Int J Obes (Lond); 2018 Nov; 42(11):1900-1911. PubMed ID: 29463916
[TBL] [Abstract][Full Text] [Related]
11. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
12. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
13. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
[TBL] [Abstract][Full Text] [Related]
14. Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan
de Lédinghen V; Hiriart JB; Vergniol J; Merrouche W; Bedossa P; Paradis V
Dig Dis Sci; 2017 Sep; 62(9):2569-2577. PubMed ID: 28577247
[TBL] [Abstract][Full Text] [Related]
15. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
[TBL] [Abstract][Full Text] [Related]
16. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
[TBL] [Abstract][Full Text] [Related]
17. Bariatric surgery during the evolution of fatty liver-A randomized clinical trial comparing gastric bypass and sleeve gastrectomy based on transient elastography.
de Barros F; Fonseca ABM
Clin Obes; 2020 Dec; 10(6):e12393. PubMed ID: 32885600
[TBL] [Abstract][Full Text] [Related]
18. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
[TBL] [Abstract][Full Text] [Related]
19. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
